Effect of high LH/FSH ratio on women with polycystic ovary syndrome undergoing in vitro maturation treatment

Amir Wiser, Fady Shehata, Hananel Holzer, Jordana H. Hyman, Einat Shalom-Paz, Weon Young Son, Togas Tulandi

Research output: Contribution to journalArticlepeer-review

Abstract

OBJECTIVE: To determine whether high luteinizing hormone/follicle-stimulating hormone (LH/FSH) ratios have a clinical impact on women with polycystic ovary syndrome (PCOS) undergoing in vitro maturation (IVM) treatment. STUDY DESIGN: Women with PCOS who underwent IVM treatment were divided into those with LH/FSH ratio > 1.5 and LH/FSH 0.5- 1.5. We analyzed baseline characteristics of the patients, number of oocytes retrieved, number of mature oocytes, and pregnancy rates. RESULTS: Women with LH/FSH ratio of > 1.5 had higher basal serum testosterone (2.2 vs. 1.4, p<0.005, CI 0.1-1.0) and estradiol (188.7±16.2 vs. 143.7±6.9, p< 0.01, CI 23-96). The antral follicle count (AFC) was also higher in the patients with high LH/FSH (46.2±3.5 vs. 32.9±1.3, p<0.001, CI 7-21). The total number of retrieved oocytes and number of mature oocytes was also significantly higher in women with LH/FSH ratio of >1.5 than in those with a lower ratio. However, the pregnancy rate in women with LH/FSH ratio of > 1.5 (16.7%) was significantly lower than in those with a ratio of 0.5- 1.5 (40.4%), p<0.05, odds ratio 0.32. CONCLUSION: PCOS patients with LH/FSH ratio of >1.5 had higher basal testosterone, E2, and AFC but decreased pregnancy rate. This could be due to the deleterious effect of LH on folliculogenesis and endometrial receptivity.

Original languageEnglish
Pages (from-to)219-223
Number of pages5
JournalThe Journal of reproductive medicine
Volume58
Issue number5-6
StatePublished - Jun 2013
Externally publishedYes

Keywords

  • Follicle-stimulating hormone
  • In vitro maturation of oocytes
  • Luteinizing hormone
  • Ovulation induction
  • Polycystic ovary syndrome

Fingerprint

Dive into the research topics of 'Effect of high LH/FSH ratio on women with polycystic ovary syndrome undergoing in vitro maturation treatment'. Together they form a unique fingerprint.

Cite this